Cathie Wood’s ARK buys Oklo and sells UiPath in active trading By Investing.com

Cathie Wood’s ARK ETFs have made significant trades on Monday, July 15, 2024, with a notable shift in their investment strategy. The funds managed by the influential investor have engaged in both buying and selling across various sectors, reflecting ARK’s dynamic approach to managing its portfolios.

Leading the day’s purchases, ARK’s ARKQ ETF invested heavily in Oklo Inc (NASDAQ:OKLO), acquiring 280,149 shares with a total dollar value of $2,412,082. This move indicates a bullish stance on the advanced nuclear energy company, which aligns with ARK’s focus on innovative and disruptive technologies.

Not far behind, ARK’s ARKG ETF increased its stake in Natera Inc (NASDAQ:), buying 17,106 shares worth $1,909,029. Natera’s focus on genetic testing and diagnostics is a sector that ARK has shown consistent interest in, as evidenced by their ongoing investments.

In the realm of therapeutics, ARK’s ARKK ETF and ARKG ETF together purchased 74,880 shares of Intellia Therapeutics Inc (NASDAQ:) for a combined value of $1,931,155. Additionally, ARK’s ARKG ETF bought 53,74 shares of Amgen Inc (NASDAQ:), totaling $1,777,880, and 57,538 shares of Beam Therapeutics Inc (NASDAQ:BEAM), amounting to $1,546,621. These trades underscore ARK’s commitment to the healthcare sector, particularly in cutting-edge genetic editing and biopharmaceuticals.

ARK also displayed confidence in the e-commerce platform Shopify Inc (NYSE:NYSE:), with the ARKW ETF purchasing 30,368 shares valued at $1,970,579. This acquisition reflects the fund’s belief in the growth potential of online retail, a sector that has seen a significant uptick since the pandemic.

On the selling side, ARK made its largest divestment from UiPath Inc (NYSE:NYSE:), with the ARKG ETF offloading 589,758 shares for a substantial $7,448,643. This sell-off suggests a strategic reallocation of assets or a possible reaction to recent performance or market conditions.

Further sales included Trimble Inc (NASDAQ:TRMB), with the ARKQ ETF selling 39,404 shares at $2,259,819, and Veracyte Inc (NASDAQ:), with the ARKW ETF parting with 98,535 shares for $2,241,671. These moves might indicate a reassessment of ARK’s positions in these companies or a broader portfolio rebalancing effort.

In smaller transactions, ARK’s ARKF ETF sold 1,895 shares of Coinbase Global Inc (NASDAQ:) for $413,147, continuing a sell trend from the previous week. Additionally, the ARKK ETF sold marginal amounts of Ginkgo Bioworks Holdings Inc (NYSE:NYSE:) and Verve Therapeutics Inc (NASDAQ:VERV), with the latter showing a consistent selling pattern over the past week.

Overall, ARK’s trading activity for the day demonstrates a focus on innovative companies with transformative potential, while also taking profits and cutting exposure in other areas. Investors following ARK’s trades are witnessing a dynamic investment strategy that seeks to capitalize on disruptive trends across various industries.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.